Interleukin-7 Receptor α Is Essential for the Development of $\gamma\delta^+$ T Cells, but Not Natural Killer Cells

By You-Wen He and Thomas R. Malek

From the Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida 33101

Summary

Mice that lack a functional γc subunit of the receptors for interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 display profound defects in lymphoid development. The IL-7/IL-7R system represents a critical interaction for conventional T and B cell development. In this report, the role of IL-7R α in the development of lymphoid lineages other than conventional T and B cells was examined. We demonstrate that $\gamma\delta^+$ T cells were absent in IL-7R α -deficient mice, whereas the development and function of natural killer cells were normal. Thus, IL-7R α function is required for the development of $\gamma\delta^+$ T cells but not natural killer cells.

ymphocyte development is critically dependent on cytokines for the expansion and differentiation of multipotential progenitors. Mutations in the yc subunit of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (1-8) in humans result in X-linked severe combined immunodeficiency (SCID) (9). This disease is characterized by the absence or greatly reduced numbers of T cells and NK cells with the presence of nonfunctional B cells (10). Mice lacking yc exhibit defects in lymphoid development that appear more severe than human X-linked SCID. These mice are deficient in the development of T cells, B cells, NK cells, Thy-1⁺ $\gamma\delta$ dendritic epidermal T cells (DETC), and intraepithelial lymphocytes (IEL) (11, 12). Because yc is shared by at least five cytokine receptors, this phenotype likely results from the disruption of the function of several cytokines. Recently, IL-7 has been identified as one key cytokine for lymphocyte development. For mice treated with mAbs to IL-7 or IL-7R α (13–15), or deficient in expression of the IL-7 or the IL-7Ra genes (16, 17), T and B cell development was blocked at very early stages. It is not known, however, whether signaling through IL-7R α is also critical for supporting the development of other lymphoid lineages, such as NK and $\gamma\delta^+$ DETC cells. In this study, this issue was examined by phenotypic and functional analysis of IL-7R α -deficient mice. We show here that $\gamma \delta^+$ T cells are absent, while the development and function of NK cells are normal in IL-7R α -deficient mice.

Materials and Methods

Animals. IL-7R α deficient mice, back-crossed for five generations to C57BL/6 mice, were kindly provided by Immunex Research and Development Corp. (Seattle, WA) (17). C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME) or obtained from the Specialized Animal Facility at the University of Miami. 5–7-wk-old age-matched C57BL/6 mice were used as controls throughout the study.

Flow Cytometric Analysis. Cells from the thymus, spleen, and skin were subjected to multicolor staining and analyzed on a FACScan[®] (Becton Dickinson & Co., Mountain View, CA) flow cytometer using LYSIS II software. Before staining, cells were incubated with an mAb to the FcR (2.4G2) to prevent nonspecific binding, and then sequentially stained with biotinylated antibodies, PE-avidin, FITC-mAbs, and Cy-Chrome-mAbs. Data were collected from 10⁴ viable cells, as determined either by a combination of forward and side scatter or by staining with propidium iodide. The following mAbs were purchased from PharMingen (San Diego, CA): biotin-GL3 (anti-γδ TCR), biotin-H57-597 (anti-αβ TCR), biotin-PK136 (anti-NK1.1), Cy-Chrome-RM-4-5 (anti-CD4), and Cy-Chrome-53-6.7 (anti-CD8a). The following antibodies were purified and labeled in our laboratory: FITC-145-2C11(anti-CD3e) and FITC-HO13.4 (anti-Thy1.2). The anti–IL-2R β mAb 5H4 was produced in our laboratory and described elsewhere (18).

NK Assay. To assay spontaneous NK activity, splenocytes were incubated with ⁵¹Cr-labeled YAC-1 target cells (10⁴) in 0.2 ml of RPMI 1640 medium containing 5% FCS in round-bottom plates for 6 h, and an aliquot (0.1 ml) of the culture fluid was counted in a gamma scintillation counter as described (19). IL-2– activated NK (LAK) activity was examined by culturing splenocytes (2×10^{6} /ml) with 500 U/ml mouse rIL-2 for 72 h at 37°C in a humidified atmosphere containing 7% CO₂ and then harvesting the adherent cells as effectors. To test the enhancement of NK activity by Poly(I):(C) (Sigma Immunochemicals, St. Louis, MO), mice were injected intraperitoneally with 100 µg Poly(I):(C) 48 and 72 h before harvesting the spleen cells. Data are calculated as previously described (19) and reported as the means of triplicate determinations with SD that varied by <10%.

Epidermal Cell Preparation. Epidermal cells were prepared by using the method described by Sullivan et al. (20). Shaved mouse torso skins were removed and trimmed of subcutaneous fat and blood vessels. Each pelt was cut into 0.5-cm strips and placed dermal side up in 0.3% trypsin (Boehringer Mannheim, Indianapolis,

289 J. Exp. Med. © The Rockefeller University Press • 0022-1007/96/07/289/05 \$2.00 Volume 184 July 1996 289-293 IN) PBS solution for 1–2 h at 37°C. Epidermal cells were carefully scraped from the dermis and placed in fresh 0.3% trypsin PBS containing 20 μ g/ml of DNAase I (Sigma) at 37°C for 10 min, followed by addition of FCS to inactivate trypsin. Cells were further disaggregated mechanically by drawing and expressing the cell suspension with a 5-ml syringe. Disaggregated cells were then centrifuged over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) at 25°C for 20 min. The cell band at the medium-Ficoll interface was harvested and washed three times with RPMI 1640 medium before FACS[®] analysis.

Results

The Development and Function of NK Cells in IL-7R α -deficient Mice. To examine whether NK cell development is normal in the IL-7R α -mutant mice, splenocytes were stained with mAbs to NK1.1 and CD3. NK-1.1⁺ CD3⁻ cells were easily detected in the IL-7Ra-deficient mice (Fig. 1). Although the percentage of NK-1.1⁺ CD3⁻ cells in the spleen from IL-7R α -deficient mice is \sim 10-fold higher than that in spleen cells from age-matched C57BL/6 mice, the actual numbers of these cells are similar for both normal and mutant mice (IL-7R α +/+: 3.3 ± 0.3 × 10⁶, n = 6; IL-7R α -/-: 3.5 ± 0.2 × 10⁶, n = 6). Since NK cells express relatively high levels of the IL-2R β chain (21), splenocytes were further analyzed with the 5H4 mAb to the IL-2R β chain. As expected, almost all the NK-1.1⁺ cells reacted with the anti-IL-2RB mAb (Fig. 1). These results indicate that NK cell development is not obviously affected by the inactivation of the IL-7Ra gene.

To determine whether NK cells in the IL-7R α mutant mice are functional, unfractionated splenocytes from untreated or Poly(I):(C)-treated mice were tested for their lytic activity on the NK-sensitive target, YAC-1 cells. Poly(I):(C) has been shown to induce IFN production from macrophages, which in turn enhance NK activity (22). Splenocytes from IL-7R α -deficient mice readily lysed YAC-1 targets at levels that were higher than detected for normal C57BL/6 mouse spleen cells. (Fig. 2 A). The stronger lytic activity by IL-7R α -deficient splenocytes is most likely caused by a higher number of NK-1.1⁺ cells added in the assay. The lysis of YAC-1 targets by splenocytes from Poly(I):(C)-treated IL-7R α -deficient and normal mice was greatly increased, reaching a maximal level at E/T of 100:1 for cells from the IL-7R α -mutant mice (Fig. 2 A). These findings indicate that the basal and Poly(I):(C)induced NK activities are not affected by the inactivation of IL-7R α gene.

High concentration of IL-2 induces NK cells to differentiate into LAK cells (23). To determine whether NK cells differentiate into LAK cells from the spleens of IL-7R α mutant mice, splenocytes from normal and IL-7R α mutant mice were cultured with a high concentration of IL-2 for 72 h, and the IL-2-activated NK activity was assessed for the adherent cells. The IL-2-activated cells from the IL-7R α -mutant mice efficiently lysed YAC-1 targets (Fig. 2 B). Thus, IL-7R α is not required for IL-2-induced NK activation. Collectively, these results demonstrate that the development and function of NK cells are not dependent on IL-7R α .

 $\gamma \delta^+$ T Cells Are Absent in IL-7R α -deficient Mice. Thy-1⁺ DETC in the skin consist of a large population of cells that almost exclusively express $\gamma \delta$ TCR (24). To examine whether $\gamma \delta^+$ DETC were present in the skin of IL-7R α mutant mice, epidermal cells were prepared and directly stained with mAbs specific for T cells. Epidermal cells from the Ficoll interface from control C57BL/6 mice contained readily detectable $\gamma \delta^+$ DETC that varied from 2 to 10% in different experiments. Similar percentages of CD3⁺ and



Figure 1. The presence of NK cells in the spleens of IL-7R α mutant mice. Splenocytes from 6-wk-old control C57BL/6 (*IL*-7R α +/+) and IL-7R α -deficient mice (*IL*-7R α -/-) were stained with biotin-NK-1.1, followed by PE-streptavidin and either FITC-anti-CD3 (A) or FITC-anti-IL-2R β c (B), and were analyzed by flow cytometry. Boxed areas are the populations referred to in the text.



Figure 2. NK activity from IL-7R α -deficient mice. (A) NK activity of fresh splenocytes from untreated and Poly(I):(C)-treated 5-6-wk-old control C57BL/6 (+/+) and IL-7R α -deficient mice (-/-). (B) NK activity of the adherent fraction of spleen cells from 5-6-wk-old control C57BL/6 (+/+) and IL-7R α -deficient mice (-/-) cultured with mIL-2 (500 U/mI) for 72 h. Data represent the mean value of triplicates from one of three similar experiments.



Figure 3. Absence of $\gamma\delta^+$ DETC in the skin of IL-7R α -mutant mice. Flow cytometric analyses were performed on epidermal cells from 6-wk-old control C57BL/6 (*IL*-7R α +/+) and IL-7R α -deficient mice (*IL*-7R α -/-). Interface epidermal cells were preincubated with an mAb to FcR, followed by staining with either biotin-anti-TCR $\gamma\delta$, PE-streptavidin, FITC-anti-CD3, or FITC-anti-Thy1.2. Percentages of positive cells are indicated.

Thy1.2⁺ cells were also detected in the control skin. A representative FACS[®] profile is shown in Fig. 3. By contrast, $\gamma\delta^+$ DETC were not detected in the skin from IL-7R α -mutant mice (Fig. 3). These epidermal cells also lacked cells that express CD3 and Thy1.2 (Fig. 3). These results were further confirmed by direct examination of epidermal sheets under fluorescence microscopy (data not shown).

TCR $\gamma\delta^+$ cells account for a very minor subset of cells in thymus and spleen (25, 26). To detect $\gamma\delta^+$ T cells in the thymus, cells were analyzed by three-color staining. CD4⁻CD8⁻ thymocytes were gated and examined for expression of $\gamma\delta$ or $\alpha\beta$ TCR. The "double-negative" thymocytes from control mice contained 20–25% CD3⁺ cells, of which 30–40% expressed $\gamma\delta$ TCR and 60–70% expressed $\alpha\beta$ TCR (Fig. 4 A). By contrast, very few CD4 CD8⁻ TCR $\gamma\delta^+$ thymocytes were detected in the IL-7R α -deficient mice, while a correspondingly higher percentage of CD4⁻CD8⁻ TCR $\alpha\beta^+$ thymocytes were found (Fig. 4 A).

Since the majority of CD4⁺ or CD8⁺ T cells in the spleen express $\alpha\beta$ TCR (26), CD3⁺CD4⁻CD8⁻ splenocytes were gated and analyzed for the expression of $\gamma\delta$ TCR. This subset accounted for ~0.7% and 0.1% of unfractionated splenocytes from the control and IL-7R α deficient mice, respectively. Within this population, 36% of the control cells expressed $\gamma\delta$ TCR, and an equal percentage of the cells expressed $\alpha\beta$ TCR (Fig. 4 *B*). In the IL-7R α -mutant mice, very few CD3⁺CD4⁻CD8⁻ splenocytes expressed $\gamma\delta$ TCR, whereas a majority of these cells expressed $\alpha\beta$ TCR (Fig. 4 B).

Discussion

Three important points emerge from this study. First, the absence of $\gamma\delta^+$ T cells and normal development and function of NK cells in IL-7R α -deficient mice indicate that inactivation of IL-7 function in γ c-mutant mice accounts for part, but not all, of the defects in the development of multiple lymphoid lineages. Second, both IL-7and thymic stromal cell-derived lymphopoeitin (TSLP) (17) are not critically involved in the development and function of NK cells. Third, signaling through IL-7R α appears more critical for the development of $\gamma\delta$ T cells than for $\alpha\beta$ T cells.

As IL-7 and IL-7R α -mutant mice exhibit severe defects in conventional T and B cell development, it is clear that signaling through the IL-7R α is critical for both T and B cell development, and that the phenotype of yc-mutant mice and human X-linked SCID is as least partially explained by a deficiency in the IL-7/IL-7R system. Furthermore, IL-7R α is a subunit for not only IL-7, but also TSLP, which shares many biological properties with IL-7 (17, 27). It is likely that the more severe phenotype in IL-7R α -mutant mice reflects the consequences of inactivation of both IL-7 and TSLP function. However, the presence of a normal number of functional NK cells in IL-7Ra-deficient mice demonstrates that the IL-7R system does not solely explain the phenotype of yc-mutant mice and indicate that the development of NK is dependent on a cytokine whose receptor uses yc, but is independent of IL-7 and IL-7Ra. Since the development of NK cells is normal in IL-2- and IL-4-deficient mice (28, 29), it is highly likely that these cytokines do not critically control NK development.

Given the tremendous heterogeneity of $\gamma\delta^+$ T cells with respect to their generation, anatomical localization, and V gene segment usages (for review see reference 24), we were surprised that no $\gamma\delta^+$ T cells were detected in the skin, thymi, and spleens of IL-7R α -mutant mice. Furthermore, in studies that have investigated the role of γc in IEL development, $\gamma\delta^+$ IELs were not detected in the small intestines of IL-7R α -deficient mice (He, Y.-W., and T.R.



291 He and Malek Brief Definitive Report

Figure 4. Absence of $\gamma \delta^+$ T cells in the spleens and thymi of IL-7R α mutant mice. (A) Thymocytes were stained with either biotin-anti-TCR $\gamma \delta$ or biotin-anti-TCR $\alpha \beta$, followed by PE-streptavidin, FITC-anti-CD4, and Cy-Chrome-anti-CD8; CD4⁻CD8⁻ "double-negative" cells were gated and analyzed for $\alpha\beta$ and $\gamma\delta$ TCR expression by collecting 5 × 10³ viable cells. (B) Splenocytes were stained with either biotin-anti-TCR $\gamma\delta$ or biotin-anti-TCR $\alpha\beta$, followed by PEstreptavidin, FITC-anti-CD3, Cy-Chrome-anti-CD4, and Cy-Chrome-anti-CD8; the CD3⁺CD4⁻CD8⁻ cells were gated and analyzed for $\alpha\beta$ and $\gamma\delta$ TCR expression by collecting 5 × 10³ viable cells. Percentages of positive cells are indicated in both panels. Malek, unpublished data). Thus, IL-7R α signaling appears to be required for the development of all $\gamma\delta^+$ T cells. Our findings are consistent with several in vitro studies that demonstrated a role for IL-7 in inducing expression of $\gamma\delta$ TCR by CD3⁻CD4⁻CD8⁻ thymocytes (30) and in supporting the growth of DETC (31). However, the precise role of IL-7R α for $\gamma\delta$ T cell development is unknown. Signaling via this receptor may be critical for commitment to the $\gamma\delta$ T cell lineage, or after commitment, it may be essential for $\gamma\delta$ TCR rearrangement.

There is an obvious dichotomy in the requirement for IL-7R α function for development of $\gamma\delta^+$ and $\alpha\beta^+$ T cells. Although the overall number of thymocytes and splenic T cells was reduced ~10-fold in the IL-7R α -mutant mice (17), essentially all the CD4⁺ or CD8⁺ mature T cells in these organs expressed $\alpha\beta$ TCR (He, Y.-W., and T.R. Malek, unpublished observation). Furthermore, correspond-

ingly higher than normal percentages of CD4-CD8- thymocytes and splenic T cells also expressed $\alpha\beta$ TCR. These data indicate that IL-7R α signaling is not essential for the rearrangement of the $\alpha\beta$ TCR. This conclusion is in contrast to the observation that IL-7 induced V(D)J rearrangement of the TCR β gene and sustained the expression of RAG-1 and RAG-2 genes in vitro in thymocyte suspensions from mouse embryos (32). When mice are treated with mAbs to IL-7, the earliest T cell precursors, i.e., CD44⁺CD25⁻CD4⁻CD8⁻ thymocytes, inefficiently make the transition to the next stage of thymocyte maturation, i.e., CD44+CD25+CD4-CD8- thymocytes (14). It is only after this time that TCR β gene rearrangement occurs (33). Thus, we favor a predominant role for IL-7R α signaling for the expansion and/or survival of the earliest T cell precursors in the thymus without an essential role in the induction of $\alpha\beta$ TCR rearrangement.

We thank Immunex for providing the IL-7R α mutant mice, Dr. Bai Liu for helping with the NK activity assay, and Ms. Christina Abolafia and Susan Grammer for helping with the preparation of epidermal cells.

This work was supported by grant R01-CA45957 from the National Institutes of Health.

Address correspondence to Dr. Thomas R. Malek, Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33101.

Received for publication 7 March 1996 and in revised form 18 April 1996.

References

- 1. Takeshita, T., H. Asao, K. Ohtani, N. Ishii, S. Kumaki, N. Tanaka, H. Munakata, M. Nakamura, and K. Sugamura. 1992. Cloning of the γ chain of the human IL-2 receptor. *Science (Wash. DC).* 257:379–382.
- Russell, S.M., A.D. Keegan, N. Harada, Y. Nakamura, M. Noguchi, P. Leland, M.C. Friedmann, A. Miyajima, R.K. Puri, W.E. Paul, and W.J. Leonard. 1993. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. *Science (Wash. DC)*. 262:1880–1883.
- Kondo, M., T. Takeshita, N. Ishii, M. Nakamura, S. Watanabe, K.-I. Arai, and K. Sugamura. 1993. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. *Science (Wash. DC)*. 262:1874–1877.
- Noguchi, M., Y. Nakamura, S.M. Russell, S.F. Ziegler, M. Tsang, X. Cao, and W.J. Leonard. 1993. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. *Science (Wash. DC)*. 262:1877–1880.
- Kondo, M., T. Takeshita, M. Higuchi, M. Nakamura, T. Sudo, S.I. Nishikawa, and K. Sugamura. 1994. Functional participation of the IL-2 receptor γ chain in IL-7 receptor complexes. *Science (Wash. DC)*. 263:1453–1454.
- Russell, S.M., J.A. Johnston, M. Noguchi, M. Kawamura, C.M. Bacon, M. Friedmann, M. Berg, D.W. McVicar, B.A. Witthuhn, O. Silvennoinen, et al. 1994. Interaction of IL-2Rβ and γc chains with Jak1 and Jak3: implications for XSCID and XCID. Science (Wash. DC). 266:1042–1044.
- 7. Kimura, Y., T. Takeshita, M. Kondo, N. Ishii, M. Nakamura, J. Van Snick, and K. Sugamura. 1995. Sharing of the

IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int. Immnol. 7:115–120.

- Giri, J.G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L.S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. *EMBO (Eur. Mol. Biol. Organ.) J.* 13:2822–2830.
- Noguchi, M., H. Yi, H.M. Rosenblatt, A.H. Filipovich, S. Adelstein, W.S. Modi, O.W. McBride, and W.J. Leonard. 1993. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. *Cell*. 73:147–157.
- Conley, M.E. 1992. Molecular approaches to analysis of X-linked immunodeficiencies. Annu. Rev. Immunol. 10:215– 238.
- Cao, X., E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsall, S.M. Russell, J. Drago, M. Noguchi, A. Grinberg, E.T. Bloom, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. *Immunity*. 2:223–238.
- 12. DiSanto, J.P., W. Muller, D. Guy-Grand, A. Fischer, and K. Rajewsky. 1995. Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor γ chain. *Proc. Natl. Acad. Sci. USA*. 92:377–381.
- Grabstein, K.H., T.J. Waldschmidt, F.D. Finkelman, B.W. Hess, A.R. Alpert, N.E. Boiani, A.E. Namen, and P.J. Morrissey. 1993. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp.

Med. 178:257-264.

- Bhatia, S.K., L.T. Tygrett, K.H. Grabstein, and T.J. Waldschmidt. 1995. The effect of in vivo IL-7 deprivation on T cell maturation. J. Exp. Med. 181:1399–1409.
- Sudo, T., S. Nishikawa, N. Ohno, N. Akiyama, M. Tamakoshi, H. Yoshida, and S.-I. Nishikawa. 1993. Expression and function of the interleukin 7 receptor in murine lymphocytes. *Proc. Natl. Acad. Sci. USA*. 90:9125–9129.
- von Freeden-Jeffry, U., P. Vieira, L.A. Lucian, T. McNeil, S.E.G. Burdach, and R. Murray. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181:1519–1526.
- Peschon, J.J., P.J. Morrissey, K.H. Grabstein, F.J. Ramsdell, E. Maraskovsky, B.C. Gliniak, L.S. Park, S.F. Ziegler, D.E. Williams, C.B. Ware, et al. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180:1955–1960.
- Malek, T.R., R.K. Furse, M.L. Fleming, A.J. Fadell, and Y.-W. He. 1995. Biochemical identity and characterization of the mouse interleukin-2 receptor β and γc subunits. J. Interferon and Cyt. Res. 15:447-454.
- Liu, B., E.R. Podack, J.P. Allison, and T.R. Malek. 1996. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 156:1117-1125.
- Sullivan, S., P.R. Bergstresser, R.E. Tigelaar, and J.W. Streilein. 1985. FACS purification of bone marrow-derived epidermal populations in mice: Langerhans cells and Thy-1⁺ dendritic cells. J. Invest. Dermatol. 84:491–495.
- Tanaka, T., M. Tsudo, H. Karasuyama, F. Kitamura, T. Kono, M. Hatakeyama, T. Taniguchi, and M. Miyasaka. 1991. A novel monoclonal antibody against murine IL-2 receptor β chain: characterization of receptor expression in normal lymphoid cells and EL-4 cells. J. Immunol. 147:2222–2228.
- Djeu, J.Y., J.A. Heinbaugh, H.T. Holden, and R.B. Herberman. 1979. Role of macrophages in the augmentation of mouse natural killer cell activity by polyI:C and interferon. J. Immunol. 122:182-188.
- 23. Chadwick, B.S., and R.G. Miller. 1991. Heterogeneity of

the lymphokine-activated killer cell phenotype. Cell. Immunol. 132:168-176.

- Allison, J.P., and W.L. Havran. 1991. The immunobiology of T cells with invariant γδ antigen receptors. Annu. Rev. Immunol. 9:679-705.
- 25. Itohara, S., N. Nakanishi, O. Kanagawa, R. Kubo, and S. Tonegawa. 1989. Monoclonal antibodies specific to native murine T-cell receptor γ/δ : analysis of γ/δ T cells during thymic ontogeny and in peripheral lymphoid organs. *Proc. Natl. Acad. Sci. USA*. 86:5094–5098.
- 26. Cron, R.Q., F. Koning, W.L. Maloy, D. Pardoll, J.E. Coligan, and J.A. Bluestone. 1988. Peripheral murine CD3⁺, CD4⁻, CD8⁻ T lymphocytes express novel T cell receptor γδ structure. J. Immunol. 145:1311-1317.
- 27. Friend, S.L., S. Hosier, A. Nelson, D. Foxworthe, D.E. Williams, and A. Farr. 1994. A thymic stromal cell line supports in vitro development of surface IgM⁺ B cells and produces a novel growth factor affecting B and T lineage cells. *Exp. Hematol.* 22:321–328.
- Kündig, T.M., H. Schorle, M.F. Bachmann, H. Hengartner, R.M. Zinkernagel, and I. Horak. 1993. Immune responses in interleukin-2-deficient mice. *Science (Wash. DC)*. 262:1059– 1061.
- Kühn, R., K. Rajewsky, and W. Muller. 1991. Generation and analysis of interleukin-4 deficient mice. *Science (Wash.* DC). 254:707-710.
- He, W., Y. Zhang, Y. Deng, and D. Kabelitz. 1995. Induction of TCR-γδ expression on triple-negative (CD3⁻4⁻8⁻) human thymocytes: comparative analysis of the effects of IL-4 and IL-7. *J. Immunol.* 154:3726–3731.
- Matsue, H., P.R. Bergstresser, and A. Takashima. 1993. Keratinocyte-derived IL-7 serves as a growth factor for dendritic epidermal T cells in mice. J. Immunol. 151:6012-6019.
- Muegge, K., M.P. Vila, and S.K. Durum. 1993. Interleukin-7: a cofactor for V(D)J rearrangement of the T cell receptor β gene. Science (Wash. DC). 261:93–95.
- Godfrey, D.I., J. Kennedy, P. Mombaerts, S. Tonegawa, and A. Zlotnik. 1994. Onset of TCR-β gene rearrganement and role of TCR-β expression during CD3⁻CD4⁻CD8⁻ thymocyte differentiation. J. Immunol. 152:4783–4792.